Time-dependent effect of hypoxia on tumor progression and liver progenitor cell markers in primary liver tumors

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Bogaerts, Eliene ^a   Heindryckx, Femke ^b   Devisscher, Lindsey ^a   Paridaens, Annelies ^a   Vandewynckel, Yves Paul ^a   Van Bussche, Anja Den ^a   Verhelst, Xavier ^a   Libbrecht, Louis ^c   Van Grunsven, Leo A ^d   Geerts, Anja ^a   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UPPSALA UNIVERSITY   (Sweden)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLOXALOYLGLYCINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOTCH RECEPTOR; PROLYL HYDROXYLASE INHIBITOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CYTOKERATIN 19; EPITHELIAL CELL ADHESION MOLECULE; MESSENGER RNA; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT TUMOR; CELL HYPOXIA; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER PROGENITOR CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEM CELL; STEM CELL NICHE; TIME; TUMOR GROWTH; ANIMAL; CELL TRANSFORMATION; CHEMICALLY INDUCED; DISEASE COURSE; DISEASE MODEL; GENETICS; HYPOXIA; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METABOLISM; PATHOLOGY; TIME FACTOR;

MUS;

ANIMALS; ANTIGENS, NEOPLASM; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIAL CELL ADHESION MOLECULE; GENE EXPRESSION; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KERATIN-19; LIVER NEOPLASMS; MALE; MICE; NEOPLASM METASTASIS; RECEPTORS, NOTCH; RNA, MESSENGER; STEM CELLS; TIME FACTORS;

EID: 84925597890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119555     Document Type: Article

References (41)

1. Van Steenkiste C, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, et al. Inhibition of Placental Growth Factor Activity Reduces the Severity of Fibrosis, Inflammation, and Portal Hypertension in Cirrhotic Mice. Hepatology. 2011; 53(5):1629-40. doi: 10.1002/hep.24238 PMID: 21520176
2. Heindryckx F, Mertens K, Charette N, Vandeghinste B, Casteleyn C, Van Steenkiste C, et al. Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer. 2010; 9.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. doi: 10.1056/NEJMoa0708857 PMID: 18650514
4. Heindryckx F, Coulon S, Terrie E, Casteleyn C, Stassen JM, Geerts A, et al. The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model. J Hepatol. 2013; 58(2):319-28. doi: 10.1016/j.jhep.2012.09.032 PMID: 23046674
5. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell. 2009; 15(3):220-31. doi: 10.1016/j.ccr.2009.01.027 PMID: 19249680
6. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis. Cancer Cell. 2009; 15 (3):232-9. doi: 10.1016/j.ccr.2009.01.021 PMID: 19249681
7. Heindryckx F, Bogaerts E, Coulon SH, Devlies H, Geerts AM, Libbrecht L, et al. Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model. Eur J Gastroenterol Hepatol. 2012; 24(9):1020-32. doi: 10.1097/MEG.0b013e3283554219 PMID: 22772092
8. Liang YJ, Zheng TS, Song RP, Wang JB, Yin DL, Wang LL, et al. Hypoxia-Mediated Sorafenib Resistance Can Be Overcome by EF24 Through Von Hippel-Lindau Tumor Suppressor-Dependent HIF-1alpha Inhibition in Hepatocellular Carcinoma. Hepatology. 2013; 57(5):1847-57. doi: 10.1002/hep.26224 PMID: 23299930
9. Fausto N. Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells. Hepatology. 2004; 39(6):1477-87. PMID: 15185286
10. Spee B, Carpino G, Schotanus BA, Katoonizadeh A, Vander Borght S, Gaudio E, et al. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut. 2010; 59(2):247-57. doi: 10.1136/gut.2009.188367 PMID: 19880964
11. Van Hul NKM, Abarca-Quinones J, Sempoux C, Horsmans Y, Leclercq IA. Relation Between Liver Progenitor Cell Expansion and Extracellular Matrix Deposition in a CDE-Induced Murine Model of Chronic Liver Injury. Hepatology. 2009; 49(5):1625-35. doi: 10.1002/hep.22820 PMID: 19296469
12. Boulter L, Govaere O, Bird TG, Radulescu S, Ramachandran P, Pellicoro A, et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med. 2012.
13. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis. 2003; 23(4):385-96. PMID: 14722815
14. Bogaerts E, Heindryckx F, Vandewynckel YP, Van Grunsven LA, Van Vlierberghe H. The roles of transforming growth factor-beta, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol. 2014; 44(4):1015-22. doi: 10.3892/ijo.2014.2286 PMID: 24504124
15. Strazzabosco M, Fabris L. The balance between Notch/Wnt signaling regulates progenitor cells' commitment during liver repair: Mystery solved? J Hepatol. 2013; 58(1):181-3. doi: 10.1016/j.jhep.2012.08.006 PMID: 22902547
16. Mathieu J, Zhang Z, Zhou WY, Wang AJ, Heddleston JM, Pinna CMA, et al. HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells. Cancer Res. 2011; 71(13):4640-52. doi: 10.1158/0008-5472.CAN-10-3320 PMID: 21712410
17. Heindryckx F, Kuchnio A, Casteleyn C, Coulon S, Olievier K, Colle I, et al. Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice. J Hepatol. 2012; 57(1):61-8. doi: 10. 1016/j.jhep.2012.02.021 PMID: 22420978
18. Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed Hepatocellular Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma in Patients Undergoing Transplantation for Hepatocellular Carcinoma. Liver Transpl. 2011; 17(8):934-42. doi: 10.1002/lt.22307 PMID: 21438129
19. Zen C, Zen Y, Mitry RR, Corbeil D, Karbanova J, O'Grady J, et al. Mixed Phenotype Hepatocellular Carcinoma After Transarterial Chemoembolization and Liver Transplantation. Liver Transpl. 2011; 17 (8):943-54. doi: 10.1002/lt.22314 PMID: 21491582
20. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, et al. Fromproteomic analysis to clinical significance- Overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics. 2004; 3(1):73-81. PMID: 14593079
21. Ma S, Lee TK, Zheng BJ, Chan K, Guan XY. CD133(+) HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008; 27(12):1749-58. PMID: 17891174
22. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003; 94(10):851-7.PMID: 14556657
23. Yang W, Wang C, Lin Y, Liu Q, Yu LX, Tang L, et al. OV6(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol. 2012; 57(3):613-20. doi: 10. 1016/j.jhep.2012.04.024 PMID: 22612999
24. Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, SieghartW, et al. Nuclear beta-Catenin Induces an Early Liver Progenitor Phenotype in Hepatocellular Carcinoma and Promotes Tumor Recurrence. Am J Pathol. 2010; 176(1):472-81. doi: 10.2353/ajpath.2010.090300 PMID: 20008139
25. Devisscher L, Hindryckx P, Olievier K, Peeters H, De Vos M, Laukens D. Inverse correlation between metallothioneins and hypoxia-inducible factor 1 alpha in colonocytes and experimental colitis. Biochem Biophys Res Commun. 2011; 416(3-4):307-12. doi: 10.1016/j.bbrc.2011.11.095 PMID: 22142848
26. Geerts AM, Vanheule E, Praet M, Van Vlierberghe H, De Vos M, Colle I. Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. Int J Exp Pathol. 2008; 89(4):251-63. doi: 10.1111/j.1365-2613.2008.00597.x PMID: 18715470
27. Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y, et al. Potential hepatic stem cells reside in EpCAM(+) cells of normal and injured mouse liver. Development. 2009; 136(11):1951-60. doi: 10.1242/dev.031369 PMID: 19429791
28. Schnell U, Cirulli V, Giepmans BNG. EpCAM: Structure and function in health and disease. Biochim Biophys Acta-Biomembr. 2013; 1828(8):1989-2001. doi: 10.1016/j.bbamem.2013.04.018 PMID: 23618806
29. Heindryckx F CS, Terrie E, Casteleyn C, Stassen J-M, Geerts A, Louis Libbrecht, Joke Allemeersch, Peter Carmeliet, Isabelle Colle & Hans Van Vlierberghe. The placental growth factor as a target against hepatocellular carcinoma in an orthotopic mouse model. J Hepatol. 2012;Submitted.
30. Govaere O, Komuta M Fau-Berkers J, Berkers J Fau-Spee B, Spee B Fau-Janssen C, Janssen C Fau-de Luca F, de Luca F Fau-Katoonizadeh A, et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. (1468-3288 (Electronic)).
31. Borght SV, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 2008; 28(10):1370-80. doi: 10. 1111/j.1478-3231.2008.01889.x PMID: 19055643
32. Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci. 2009; 66(22):3539-54. doi: 10.1007/s00018-009-0147-7 PMID: 19756382
33. Ke QD, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006; 70(5):1469-80. PMID: 16887934
34. Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol. 2005; 39(5):401-12. PMID: 15815209
35. Copple BL. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver Int. 2010; 30(5):669-82. doi: 10.1111/j.1478-3231.2010.02205.x PMID: 20158611
36. Lau CK, Yang ZF, Ho DW, Ng MN, Yeoh GCT, Poon RTP, et al. An Akt/Hypoxia-Inducible Factor-1 alpha/Platelet-Derived Growth Factor-BB Autocrine Loop Mediates Hypoxia-Induced Chemoresistance in Liver Cancer Cells and Tumorigenic Hepatic Progenitor Cells. Clin Cancer Res. 2009; 15(10):3462-71. doi: 10.1158/1078-0432.CCR-08-2127 PMID: 19447872
37. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006; 49(2):138-51. PMID: 16879391
38. Timme CR, Gruidl M, Yeatman TJ. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells. Apoptosis. 2013; 18(10):1163-74. doi: 10.1007/s10495-013-0883-x PMID: 23887890
39. Zhang CC, Yan ZM, Zong Q, Fang DD, Painter C, Zhang Q, et al. Synergistic Effect of the gamma- Secretase Inhibitor PF-03084014 and Docetaxel in Breast Cancer Models. Stem Cells Transl Med. 2013; 2(3):233-42. doi: 10.5966/sctm.2012-0096 PMID: 23408105
40. Michalopoulos GK, Barua L, Bowen WC. Transdifferentiation of rat hepatocytes into biliary cells after bile duct ligation and toxic biliary injury. Hepatology. 2005; 41(3):535-44. PMID: 15726663
41. Michalopoulos GK, Bowen WC, Mule K, Lopez-Talavera JC, Mars W. Hepatocytes undergo phenotypic transformation to biliary epithelium in organoid cultures. Hepatology. 2002; 36(2):278-83. PMID: 12143035